![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Authorizes Novavax COVID-19 Vaccine in Adolescents
FDA Authorizes Novavax COVID-19 Vaccine in Adolescents
August 23, 2022
The FDA has expanded its Emergency Use Authorization (EUA) of Novavax’s COVID-19 vaccine to include adolescents between the ages of 12 and 17 years old.
The EUA allows this age group to receive a two-dose primary series of the vaccine.
The agency’s decision was based on data from an ongoing late-stage clinical trial in which the vaccine demonstrated efficacy of 78.29 percent at a time when the Delta variant was the predominant variant in the U.S.
Unlike the messenger RNA-based vaccines from Pfizer-BioNTech and Moderna, the Novavax vaccine is based on recombinant nanoparticle technology.
Upcoming Events
-
21Oct